AR125470A1 - Composición farmacéutica de pembrolizumab y su uso - Google Patents
Composición farmacéutica de pembrolizumab y su usoInfo
- Publication number
- AR125470A1 AR125470A1 ARP220101106A ARP220101106A AR125470A1 AR 125470 A1 AR125470 A1 AR 125470A1 AR P220101106 A ARP220101106 A AR P220101106A AR P220101106 A ARP220101106 A AR P220101106A AR 125470 A1 AR125470 A1 AR 125470A1
- Authority
- AR
- Argentina
- Prior art keywords
- pembrolizumab
- compositions
- pharmaceutical composition
- histidine
- poloxamer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La invención se refiere al campo de la farmacia y la medicina, específicamente a las composiciones farmacéuticas del anticuerpo anti-PD-1 pembrolizumab, que pueden ser composiciones acuosas o liofilizadas. La invención se refiere además al uso de dichas composiciones para el tratamiento de neoplasias malignas o enfermedades infecciosas, así como al uso de dichas composiciones para producir un medicamento destinado a tratar neoplasias malignas o enfermedades infecciosas. Reivindicación 1: Una composición farmacéutica de pembrolizumab que comprende: (i) pembrolizumab; (ii) histidina (iii) clorhidrato de histidina monohidratado; (iv) glicina; (v) trehalosa y poloxamer 188, o prolina; y (vi) agua para inyección. Reivindicación 9: La composición farmacéutica según la reivindicación 1, que comprende: (i) 5 - 50 mg/ml de pembrolizumab; (ii) 0,087 - 0,432 mg/ml de histidina; (iii) 0,464 - 0,931 mg/ml de clorhidrato de histidina monohidratado; (iv) 1 - 2 mg/ml de glicina; (v) 70 - 130 mg/ml de trehalosa y 0,8 - 1,2 mg/ml de poloxamer 188, o 20 - 34 mg/ml de prolina; y (vi) agua para inyección a 1 ml.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021112111A RU2791857C2 (ru) | 2021-04-27 | Фармацевтическая композиция пембролизумаба и ее применение |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125470A1 true AR125470A1 (es) | 2023-07-19 |
Family
ID=83848424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101106A AR125470A1 (es) | 2021-04-27 | 2022-04-27 | Composición farmacéutica de pembrolizumab y su uso |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4329729A1 (es) |
CN (1) | CN117835965A (es) |
AR (1) | AR125470A1 (es) |
CO (1) | CO2023014166A2 (es) |
CR (1) | CR20230527A (es) |
EC (1) | ECSP23081880A (es) |
MA (1) | MA62939A1 (es) |
TW (1) | TW202308692A (es) |
WO (1) | WO2022231481A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE050894T2 (hu) * | 2015-04-17 | 2021-01-28 | Bristol Myers Squibb Co | Kompozíciók, amelyek tartalmazzák ipilimumab és nivolumab kombinációját |
US11608357B2 (en) * | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
CA3063324A1 (en) * | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
-
2022
- 2022-04-26 TW TW111115864A patent/TW202308692A/zh unknown
- 2022-04-27 MA MA62939A patent/MA62939A1/fr unknown
- 2022-04-27 CR CR20230527A patent/CR20230527A/es unknown
- 2022-04-27 EP EP22796265.1A patent/EP4329729A1/en active Pending
- 2022-04-27 CN CN202280030892.2A patent/CN117835965A/zh active Pending
- 2022-04-27 WO PCT/RU2022/050140 patent/WO2022231481A1/en active Application Filing
- 2022-04-27 AR ARP220101106A patent/AR125470A1/es unknown
-
2023
- 2023-10-23 CO CONC2023/0014166A patent/CO2023014166A2/es unknown
- 2023-10-25 EC ECSENADI202381880A patent/ECSP23081880A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP23081880A (es) | 2023-11-30 |
CO2023014166A2 (es) | 2024-02-05 |
CN117835965A (zh) | 2024-04-05 |
MA62939A1 (fr) | 2024-02-29 |
TW202308692A (zh) | 2023-03-01 |
EP4329729A1 (en) | 2024-03-06 |
CR20230527A (es) | 2024-02-13 |
WO2022231481A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2508290T3 (es) | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo | |
CL2020001579A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. (divisional solicitud 201303145) | |
AR052198A1 (es) | Formulaciones anticuerpo anti a beta | |
CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
AR112480A1 (es) | Composiciones de glp-1 y sus usos | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CO6480980A2 (es) | Composicion farmaceutica para un inhibidor de proteasa del virus de la hepatitis c | |
CO6311007A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
EA201071039A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40 | |
AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
UY31826A (es) | Compuesto peptídico y su uso | |
AR125470A1 (es) | Composición farmacéutica de pembrolizumab y su uso | |
FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia |